Acute Hypercalcaemia Protocol

Hydrate, block, eliminate: the three steps in order, and what to check before each · v1.1

  • Enter the calcium and albumin, the ECG findings and symptoms, the renal function and volume status, then tick the suspected aetiology.
  • You get a stepwise emergency protocol covering hydration, anti-resorptive therapy and the indications for dialysis.
  • The aetiology you tick drives the cause-directed step, so tick it only where you have a reason for it.
  • It lowers the calcium, not the cause. Until the cause is treated the calcium will come back.

  • Children and adolescents under 18.
  • The cause of the hypercalcaemia. It takes your suspicion as an input and reasons forward from it, so a wrong suspicion produces a confidently wrong cause-directed step.
  • The staging or treatment of a malignancy, and the decision to send a patient for parathyroid surgery.
  • The dialysis prescription. It names the indication and stops. The prescription, and the decision to start, belong with nephrology.
  • A dose for any agent it cannot confirm is obtainable in India.
1. Calcium & Albumin
2. Clinical Status
3. Suspected Aetiology

1. The Two Causes That Cover 90%

Primary hyperparathyroidism and malignancy account for approximately 90% of all hypercalcaemia. Separating the two is the whole of the early work, because the treatments have nothing in common. PTH is the discriminator: PTH elevated or inappropriately normal = primary hyperparathyroidism; PTH suppressed (low) = malignancy or other non-PTH cause. Always send PTH, PTHrP, 25-OH vitamin D, and 1,25-dihydroxyvitamin D together.

FeaturePrimary HyperparathyroidismMalignancy-Associated
OnsetChronic, indolentAcute, rapid rise
Calcium levelUsually mild (10.5-12 mg/dL)Often severe (> 14 mg/dL)
PTHElevated or inappropriately normalSuppressed (low)
PTHrPNormalElevated (humoral hypercalcaemia of malignancy)
ChlorideElevated (> 103) due to bicarbonaturiaNormal
Definitive treatmentParathyroidectomyTreat underlying malignancy

2. The Physiology of Dehydration in Hypercalcaemia

Hypercalcaemia sets up a vicious cycle of dehydration, and IV saline breaks the cycle by restoring GFR and promoting calciuresis.

  • Calcium impairs renal concentrating ability (nephrogenic diabetes insipidus), causing polyuria.
  • Hypercalcaemia causes nausea and vomiting, reducing fluid intake.
  • Dehydration reduces GFR, decreasing renal calcium excretion.
  • Higher serum calcium worsens symptoms further.

3. Bisphosphonate Therapy: Potent, and Slow

Zoledronic acid (Zometa) 4 mg IV over 15 minutes is the most potent bisphosphonate available. It inhibits osteoclast-mediated bone resorption. However, its onset is 2 to 4 days (peak effect at 4 to 7 days). This is why calcitonin is used as a bridge (onset 4 to 6 hours) while waiting for bisphosphonate effect. Duration: 2 to 4 weeks per dose.

Alternative: Pamidronate 60 to 90 mg IV over 2 to 4 hours. Slightly less potent but available at lower cost in Indian hospitals.

Bisphosphonate Contraindication: In severe renal impairment (eGFR < 30 or Cr > 4.5 mg/dL), zoledronic acid carries significant nephrotoxicity risk. Use Denosumab 120 mg SC instead (RANKL inhibitor, not renally cleared). Onset: 2 to 4 days.

4. Stones, Bones, Groans and Psychiatric Overtones

The classic mnemonic for the symptoms of hypercalcaemia.

  • Stones: nephrolithiasis, nephrocalcinosis.
  • Bones: bone pain, osteitis fibrosa cystica, pathological fractures.
  • Groans: abdominal pain, constipation, nausea, pancreatitis, peptic ulcer disease.
  • Psychiatric overtones: anxiety, depression, confusion, psychosis, coma.
  • Also: polyuria, polydipsia, shortened QT, band keratopathy.

5. Hypercalcaemia in TB and Granulomatous Disease

In Indian hospitals, tuberculosis is an important and often overlooked cause of hypercalcaemia. Activated macrophages in granulomata express 1-alpha hydroxylase, converting 25-OH vitamin D to active 1,25-dihydroxyvitamin D independently of PTH regulation. The result: unregulated calcium absorption. Check 1,25-dihydroxyvitamin D (will be high) and PTH (will be suppressed). Treatment: corticosteroids (Prednisolone 20 to 40 mg/day) rapidly reduce 1,25-D production and lower calcium. Also seen in sarcoidosis, granulomatosis with polyangiitis, and fungal infections.

Abbreviations: AKI (Acute Kidney Injury) · ATPase (Adenosine Triphosphatase) · AV (Atrioventricular) · BD (Twice Daily) · Ca (Calcium) · CKD (Chronic Kidney Disease) · Cr (Creatinine) · ECG (Electrocardiogram) · eGFR (Estimated Glomerular Filtration Rate) · GFR (Glomerular Filtration Rate) · ICU (Intensive Care Unit) · IM (Intramuscular) · IV (Intravenous) · Na (Sodium) · NaCl (Sodium Chloride) · NF-kB (Nuclear Factor Kappa-B) · NS (Normal Saline) · PHPT (Primary Hyperparathyroidism) · PO (Per Os) · PTH (Parathyroid Hormone) · PTHrP (Parathyroid Hormone-related Peptide) · RANKL (Receptor Activator of NF-kB Ligand) · SC (Subcutaneous) · SPEP (Serum Protein Electrophoresis) · TB (Tuberculosis) · TdP (Torsades de Pointes) · UPEP (Urine Protein Electrophoresis) · 25-OH (25-Hydroxy) · 1,25-D (1,25-Dihydroxyvitamin D)
References
  1. Minisola S, Pepe J, Piemonte S, Cipriani C. The diagnosis and management of hypercalcaemia. BMJ. 2015;350:h2723.
  2. Rosner MH, Dalkin AC. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia. Clin J Am Soc Nephrol. 2012;7(10):1722-1729.
  3. Maier JD, Levine SN. Hypercalcemia in the Intensive Care Unit: A Review of Pathophysiology, Diagnosis, and Modern Therapy. J Intensive Care Med. 2015;30(5):235-252.
  4. Walker MD, Shane E. Hypercalcemia: A Review. JAMA. 2022;328(16):1624-1636.
  5. Sharma OP. Hypercalcemia in granulomatous disorders: a clinical review. Curr Opin Pulm Med. 2000;6(5):442-447.
  6. Zagzag J, Hu MI, Fisher SB, Perrier ND. Hypercalcemia and cancer: differential diagnosis and treatment. CA Cancer J Clin. 2018;68(5):377-386.
  7. Bilezikian JP, Khan AA, Silverberg SJ, et al. Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the Fifth International Workshop. J Bone Miner Res. 2022;37(11):2293-2314.
  8. LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for hypercalcemia, an unproven yet common practice. Ann Intern Med. 2008;149(4):259-263.
  9. Turner J, Gittoes N, Selby P; Society for Endocrinology Clinical Committee. Society for Endocrinology Endocrine Emergency Guidance: emergency management of acute hypocalcaemia in adult patients. Endocr Connect. 2016;5(5):G7-G8.
How to Cite This Tool

DOIhttps://doi.org/10.5281/zenodo.22401524

AMA Style:Umakanth S. Acute Hypercalcaemia Protocol. Version 1.1. MEDiscuss Clinical Decision Support System. Published 2026. Accessed . https://mediscuss.org/cdss/acute-hypercalcaemia. doi:10.5281/zenodo.22401524

Vancouver Style:Umakanth S. Acute Hypercalcaemia Protocol [Internet]. Version 1.1. MEDiscuss.org; 2026 [cited ]. Available from: https://mediscuss.org/cdss/acute-hypercalcaemia. doi:10.5281/zenodo.22401524

Disclaimer and scope
Disclaimer: This decision-support system is written for healthcare professionals. It does not substitute clinical judgment, and the treating physician retains absolute responsibility for every diagnostic, dosing and therapeutic decision. The algorithms are built on the evidence as it stands, and the evidence moves. Verify the output against your current institutional protocol, and against the patient in front of you.
© 2026 MEDiscuss.org. All rights reserved. Provided free of charge for clinical use. Unauthorised reproduction or redistribution is strictly prohibited.
Category Therapeutic & Management PathwaysProtocol
Specialties Internal Medicine, Oncology, Nephrology, Critical Care

Written and maintained by

Dr Shashikiran Umakanth

Last revised 24 August 2026

How these tools are written and reviewed

Related Clinical Tools
Combined Electrolyte PanelAKI & CKD Staging PathwayGlucocorticoid Converter